SOURCE: Clinical Ink

Clinical Ink

March 14, 2014 09:34 ET

Clinical Ink Announces eSource Demand Grew More Than 300% in 2013

A Proven, User-Friendly eSource Solution, SureSource® Reduces Clinical Trial Costs and Shortens Development Timelines for Life Sciences Companies

WINSTON-SALEM, NC--(Marketwired - Mar 14, 2014) - Clinical Ink, an innovation-driven eSource solutions company, today announced that global demand for the company's SureSource solution grew 336 percent in 2013. As the first and only native-electronic eSource platform, SureSource replaces paper documentation in clinical research to dramatically reduce R&D costs while shortening timelines, improving data quality and patient safety.

"The dramatic growth of SureSource demand and deployments around the world reaffirms the value Clinical Ink is providing to the life sciences industry," said Ed Seguine, CEO, Clinical Ink. "We are pleased to report triple-digit growth in 2013 for all areas of implementation -- excluding support calls -- which speaks to the intuitive design and functionality of SureSource as a user-friendly eSource solution."

Clinical Ink announced the following additional implementation highlights for its SureSource tablets in 2013, all of which reflect triple-digit growth, including:

  • Total Subjects grew 248%, from 2,350 to 8,200
  • Total Visits grew 336%, from 20,500 to 89,500
  • Total Tablets grew 305%, from 185 to 750
  • Total Studies grew 200%, from 13 to 39
  • Total Users grew 157%, from 700 to 1,800

SureSource offers the freedom to work without regard to connectivity, while allowing fast and secure electronic transmission of source documents and data, making it ideal for clinical research in remote locations. Clinical research sites located in 14 countries around the world used Clinical Ink's SureSource solution in 2013. An interactive map (SureSourceInteractiveMap) shows growth in global SureSource deployment from 2013-14. 

Developed in accordance with the most recent Food and Drug Administration (FDA) guidance ("Electronic Source Data in Clinical Investigations"), Clinical Ink's SureSource technology is the first purpose-built solution that meets all FDA requirements for eSource. SureSource has been proven to reduce the cost of clinical research and speed timelines by eliminating Source Data Verification (SDV); reducing data queries up to 70 percent; and minimizing monitoring time by nearly 40 percent. 

About Clinical Ink
With offices in Winston-Salem, NC and Philadelphia, PA, Clinical Ink is an innovation-driven eSource solutions company committed to delivering technology that makes clinical research easier for sites, sponsors, subjects and regulators. Developers of SureSource™, the first purpose-built electronic source record providing cleaner data more quickly, Clinical Ink is dedicated to eliminating paper documentation in clinical research. Additional information about Clinical Ink is available at www.clinicalink.com or by calling toll-free 800-301-5033.

Contact Information